8-K filed March 4, 2025, 6:59 PM ET ticker INDV CIK 0001625297

leadership confidence high sentiment neutral materiality 0.70

Indivior appoints Joe Ciaffoni as CEO, reduces board to 7, enters amended Oaktree deal

Indivior Pharmaceuticals, Inc.

Joe Ciaffoni appointed CEO effective after 2025 AGM but no later than Aug 1, 2025; Mark Crossley remains CEO until then.
Ciaffoni gets base salary $1,050,000, bonus target 100% of salary, max 200%; on-hire PSUs worth 12x salary (up to 1.575M shares) and RSUs 4x salary (up to 525K shares).
Board reduced to 7 directors at 2025 AGM; Peter Bains and Jo LeCouilliard not standing for re-election; Robert Schriesheim resigned effective March 2.
Amended relationship with Oaktree: board to be 8 after search for one new independent director by July 1; Daniel Ninivaggi chairs Nomination Committee.
Barbara Ryan to succeed Jo LeCouilliard as Chair of Compensation Committee after the 2025 AGM.

item 1.01 item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jo LeCouilliard

Non-Executive Director

INDV · Indivior Pharmaceuticals, Inc.

Filed: March 4, 2025, 6:59 PM ET

Peter Bains and Jo LeCouilliard have decided not to stand for re-election at the Company’s Annual General Meeting.

Appointed

Joe Ciaffoni

Chief Executive Officer

INDV · Indivior Pharmaceuticals, Inc.

Filed: March 4, 2025, 6:59 PM ET

the announcement on February 27, 2025 of the appointment of Joe Ciaffoni as Chief Executive Officer of the Company

Departed

Peter Bains

Non-Executive Director

INDV · Indivior Pharmaceuticals, Inc.

Filed: March 4, 2025, 6:59 PM ET

Peter Bains and Jo LeCouilliard have decided not to stand for re-election at the Company’s Annual General Meeting.

Departed

Robert Schriesheim

Independent Non-Executive Director

INDV · Indivior Pharmaceuticals, Inc.

Effective: 2025-03-02
Filed: March 4, 2025, 6:59 PM ET

Robert Schriesheim notified the Board of his resignation therefrom on March 2, 2025 with immediate effect.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.9

Jo LeCouilliard departed as Non-Executive Director at Indivior Pharmaceuticals, Inc..

Action: decided not to stand for re-election
Role: Non-Executive Director

Exact text from the filing

Peter Bains and Jo LeCouilliard have decided not to stand for re-election at the Company’s Annual General Meeting.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Joe Ciaffoni was appointed as Chief Executive Officer at Indivior Pharmaceuticals, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

the announcement on February 27, 2025 of the appointment of Joe Ciaffoni as Chief Executive Officer of the Company

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Peter Bains departed as Non-Executive Director at Indivior Pharmaceuticals, Inc..

Action: decided not to stand for re-election
Role: Non-Executive Director

Exact text from the filing

Peter Bains and Jo LeCouilliard have decided not to stand for re-election at the Company’s Annual General Meeting.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Schriesheim resigned as Independent Non-Executive Director at Indivior Pharmaceuticals, Inc..

Action: resigned
Role: Independent Non-Executive Director

Exact text from the filing

Robert Schriesheim notified the Board of his resignation therefrom on March 2, 2025 with immediate effect.

View on SEC.gov

Indivior Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001625297-25-000021

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.